Arrowhead Pharmaceuticals (ARWR) director files Form 3 showing zero share ownership

Rhea-AI Filing Summary

Arrowhead Pharmaceuticals director Matthew Gregory Cohen has filed an initial Form 3 indicating no current ownership of the company’s Common Stock. The filing lists a holding entry in Common Stock with total shares following the report shown as 0. This is a baseline disclosure of his position as a newly reported insider, rather than a buy or sell transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Cohen Matthew Gregory

Role null

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 0 shares (Direct, null)

Footnotes (1)

Key Figures

Total shares following report: 0 shares Transaction entries: 1 holding entry Reported buy transactions: 0 +1 more

4 metrics

Total shares following report 0 shares Common Stock position on Form 3

Transaction entries 1 holding entry Form 3 Common Stock line

Reported buy transactions 0 transactionSummary buyCount

Reported sell transactions 0 transactionSummary sellCount

Key Terms

Form 3, Common Stock, reporting person

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3):"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

reporting person regulatory

""reportingPersons": [{"name": "Cohen Matthew Gregory""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Cohen Matthew Gregory

(Last) (First) (Middle)

177 EAST COLORADO BLVD STE 700

(Street)

PASADENA CALIFORNIA 91105

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/15/2026

3. Issuer Name and Ticker or Trading Symbol
ARROWHEAD PHARMACEUTICALS, INC. [ ARWR ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/Matthew Gregory Cohen	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Matthew Gregory Cohen’s Form 3 filing for ARWR show?

The Form 3 shows that Matthew Gregory Cohen, a director of Arrowhead Pharmaceuticals, reported ownership of 0 shares of Common Stock. This establishes his initial disclosed position as an insider under SEC rules, without any reported purchases or sales.

Did Matthew Gregory Cohen buy or sell Arrowhead Pharmaceuticals (ARWR) stock in this Form 3?

No, the Form 3 does not report any buy or sell transactions. It lists a holding entry in Common Stock with total shares following the report at 0, serving only as an initial ownership statement rather than a trade report.

What role does Matthew Gregory Cohen have at Arrowhead Pharmaceuticals (ARWR)?

Matthew Gregory Cohen is identified as a director of Arrowhead Pharmaceuticals. As a company insider, he must report his holdings and certain transactions in the company’s securities to the SEC using Forms 3, 4, and 5 as required.

What is the significance of reporting 0 shares on a Form 3 for ARWR?

Reporting 0 shares on Form 3 means the insider currently holds no reportable Common Stock at the time of this baseline filing. It provides a starting point so any future changes in his ownership can be tracked against this disclosed position.

Does this ARWR Form 3 include any derivative securities for Matthew Gregory Cohen?

No derivative securities are shown in the provided data for this Form 3. The derivative summary is empty, and the only security title listed is Common Stock, with total shares following the report indicated as 0.